In addition, selective IDO1 blockade may not be sufficient to alleviate tumor immunosuppression, and IDO2/TDO may serve as an enzyme with a potential compensatory mechanism to attenuate the efficacy of epacadostat, a possible reason for its failure of phase III clinical trial. This evidence concerns the gene IDO1 and neoplasm.